Living with Psoriatic Arthritis

“Living with PsA” is a syndicated report which offers valuable insights into patient attitudes and behaviour.

We recognise pharma brands need access to unique patient insights if they are to develop effective products, treatments and relevant communications messages. Living with PsA is designed to provide in-depth understanding of the PsA disease patient journey, from diagnosis through treatment and ongoing management. The report unveils patients attitudes, needs and support required at key stages of the journey.

Gain an in-depth understanding of:

• The PsA patient
• Diagnosis
• Treatment
• Relationship with HCP
• Unmet needs and support desired
• Awareness of new treatments
• Information sought on PsA
• Segmentation analysis

Methodology 

Living with Psoriatic Arthritis EU

Methodology	Quant: 30-minute online survey with patients living with PsA Qual: 30-minute qualitative telephone interviews
Countries	France	Germany	Italy	Spain	UK	Total
Total	53	52	54	53	54	267
Sample considerations	Patients diagnosed with PsA; 112 male; 140 female Adult patients age split 18-39 years (27%), 40-60 years (58%), 61+ years (15%) Quotas to capture patients receiving cDMARDs-only (50%) and advanced therapies (biologics, biosimilars, PDE4 inhibitors and JAK inhibitors) (50%)